Compare · RXST vs STAA
RXST vs STAA
Side-by-side comparison of RxSight Inc. (RXST) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RXST and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- STAA is the larger of the two at $1.16B, about 4.4x RXST ($266.2M).
- STAA has been more active in the news (11 items in the past 4 weeks vs 5 for RXST).
- Both have 25 recent analyst ratings on file.
- Company
- RxSight Inc.
- STAAR Surgical Company
- Price
- $6.41+2.40%
- $23.17-0.28%
- Market cap
- $266.2M
- $1.16B
- 1M return
- +13.35%
- -
- 1Y return
- -24.54%
- -
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 5
- 11
- Recent ratings
- 25
- 25
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest RXST
- Amendment: SEC Form SC TO-I/A filed by RxSight Inc.
- SEC Form SC TO-I filed by RxSight Inc.
- SEC Form 10-Q filed by RxSight Inc.
- RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
- RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
- SEC Form 4 filed by President and CEO Mottiwala Aziz
- SEC Form 3 filed by new insider Mottiwala Aziz
- SEC Form S-8 filed by RxSight Inc.
- RxSight Inc. filed SEC Form 8-K: Regulation FD Disclosure
Latest STAA
- Chief Development Officer Michna Magda exercised 6,599 shares at a strike of $4.36 and covered exercise/tax liability with 3,356 shares, increasing direct ownership by 9% to 41,343 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 5,233 shares and covered exercise/tax liability with 2,662 shares, increasing direct ownership by 7% to 38,910 units (SEC Form 4)
- President and CEO Foust Warren converted options into 10,997 shares and covered exercise/tax liability with 5,595 shares, increasing direct ownership by 11% to 95,816 units (SEC Form 4)
- SEC Form 10-Q filed by STAAR Surgical Company
- STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Reports Second Quarter 2026 Results
- STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- President and CEO Foust Warren converted options into 20,787 shares and covered exercise/tax liability with 10,576 shares, increasing direct ownership by 13% to 86,556 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 34,742 shares and covered exercise/tax liability with 17,056 shares, increasing direct ownership by 95% to 36,339 units (SEC Form 4)
- STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer